Drug interactions between Reyataz and Videx
Results for the following 2 drugs: |
|
|---|---|
| Reyataz (atazanavir) | |
| Videx (didanosine) | |
Interactions between your selected drugs
didanosine ↔ atazanavir
Applies to:Videx (didanosine) and Reyataz (atazanavir)
ADJUST DOSING INTERVAL: Concurrent administration of didanosine buffered tablets or powder or the pediatric oral solution may significantly decrease the oral bioavailability of atazanavir. Atazanavir solubility decreases with increasing pH, thus buffering agents in the didanosine formulations may interfere with dissolution of the drug. In 32 study subjects, simultaneous administration of didanosine buffered tablets (200 mg single dose) and stavudine (40 mg single dose) reduced the plasma concentrations of atazanavir (400 mg single dose) by over 80% compared to administration of atazanavir alone. The interaction was not observed when atazanavir was administered one hour after didanosine and stavudine. Atazanavir also had no significant effects on the pharmacokinetics of didanosine or stavudine during concurrent administration.
MANAGEMENT: Atazanavir should be administered, with food, 2 hours before or 1 hour after didanosine buffered formulations. Didanosine delayed-release capsules are not buffered and are not expected to cause this interaction. However, because didanosine should be administered on an empty stomach, the capsules should also be administered at different times from atazanavir.
See also...
Drug Interaction Classification
The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
